In this article
Dr. Thomas A. Steitz, co-winner of the 2009 Nobel Prize in Chemistry, passed away on October 9, 2018, at the age of 78, after a battle with pancreatic cancer. His death was a profound loss for the global scientific community — and there is a painful irony in the fact that a man who spent decades unlocking the molecular secrets of life ultimately fell to one of the diseases his work may one day help defeat.
Steitz dedicated much of his career to studying the ribosome, a molecular machine found inside every living cell that reads genetic instructions and uses them to build proteins. Using X-ray crystallography, he and his colleagues mapped the ribosome's structure at the atomic level — work that earned him the Nobel Prize alongside Venkatraman Ramakrishnan and Ada Yonath, and opened an entirely new window into how diseases like cancer develop at their most fundamental level.
The Pancreatic Cancer Action Network (PanCAN) expressed deep gratitude for Steitz's contributions to cell and molecular biology and extended its condolences to his family, friends, and colleagues.
Pancreatic cancer begins when mutations accumulate in the DNA of pancreatic cells. When these corrupted genetic instructions pass through the ribosome, it produces abnormal proteins that signal cells to divide uncontrollably, block natural cell death, and fuel the spread of tumors. This is why Steitz's atomic-level understanding of the ribosome matters so directly to cancer research — knowing how proteins are built is the first step toward knowing how to stop the wrong ones.
Researchers are now designing targeted therapies that block the activity of these abnormal proteins without harming healthy cells. Promising avenues include KRAS inhibitors, which target a mutation found in over 90% of pancreatic cancer cases, and PARP inhibitors for patients with inherited BRCA mutations. While pancreatic cancer remains one of the most difficult cancers to treat — largely due to late-stage diagnosis — the molecular foundation laid by researchers like Steitz continues to guide the development of more precise, effective treatments. His work is a powerful reminder that fundamental science, even at the atomic level, can carry life-changing consequences for patients.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Sai Sree
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.